XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue- Gilead Science Inc (Details) - USD ($)
$ in Thousands
 3 Months Ended 7 Months Ended 9 Months Ended
Oct. 14, 2022
Sep. 30, 2023
Sep. 30, 2022
Jul. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Collaboration And Other Agreements [Line Items]              
Revenues   $ 10,397 $ 41,734   $ 48,029 $ 78,842  
Deferred revenue, current   18,584     18,584   $ 9,988
Deferred revenue, net of current portion   64,260     64,260   59,480
Gilead | 2022 Gilead Collaboration And License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment       $ 60,000      
Revenues   400     1,000    
Deferred revenue   58,900     58,900   59,800
Deferred revenue, current   2,200     2,200   1,800
Deferred revenue, net of current portion     $ 56,700     $ 56,700 $ 58,000
Potential target nomination, option fees and milestone payments $ 1,700,000            
Gilead | Gilead First Research Program              
Collaboration And Other Agreements [Line Items]              
Revenues   100     100    
Deferred revenue   15,600     15,600    
Deferred revenue, current   10,000     10,000    
Deferred revenue, net of current portion   5,600     5,600    
Revenue, Remaining Performance Obligation, Amount   15,700     15,700    
Potential option fees   $ 10,000     $ 10,000